Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Acquisition
Carlyle Bets On Piramal Pharma • Source: Shutterstock

Global investment firm The Carlyle Group is acquiring 20% in the Piramal group’s pharma business for around $490m, setting the stage for the Indian group to pursue an ambitious growth strategy including buyouts both on home turf and internationally.

The transaction ends months of build-up around an imminent deal involving Piramal, which was also speculated to have had private...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip